UNSPSC 51431606: Metirosine or metyrosine

This classification denotes a tyrosine hydroxylase inhibitor with the molecular formula C10H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DOQ0J0TPF7, chemically known as l-tyrosine, alpha-methyl-, (-)- but generally known as metirosine, which bears US NIH Compound Identifier 12650. European Medicines Agency schedules Metirosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08894MIG. The term METIROSINE is an International Non-Proprietary Name.

UNSPSC 51431606 Metirosine or metyrosine is a Commodity code covering pharmaceutical active ingredients and finished medications. State and local governments procure under this code primarily through their public health, emergency medical services, and pharmacy benefit programs. The City of Tampa's Fire Rescue service and Texas Health and Human Services Commission both sought medications under related procurement authorities, with the latter exploring direct-to-manufacturer pharmacy supply chains. Issuing bodies include municipal fire departments, state health agencies, and cooperative purchasing alliances serving multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, represents a significant buying vehicle for pharmaceutical procurement across member states. Scope of work covers sealed-bid procurement of specific medications with firm pricing, authorized wholesaler distribution, compliance with cGMP and FDA requirements, and performance guarantees including expiration-date warranties and replacement obligations.

Recent activity clusters in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department posted IFB 26P00188 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) with a response date of April 8, 2026 and an estimated contract value of $40,000, offering a 5 percent bid discount for Small Local Business Enterprise (SLBE) participants. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to assess vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels—a preliminary market-intelligence phase rather than a formal award solicitation. The Minnesota Multistate Cooperative Purchasing Alliance posted RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson), with a response deadline of March 26, 2026 and contract effectiveness July 1, 2026. Pricing evaluation weighted price competitiveness at 75 percent, with vendors paying a 3 percent administrative fee and facing performance penalties of $200 to $1,500 per violation.